Max Healthcare inks MOU with Anuva for genomic-based research on various diseases

New Delhi: Max Healthcare and Anuva announced that they have entered into a Memorandum of Understanding (MoU) to conduct genomic-based research on various communicable and non-communicable diseases in India. The MoU was signed by Rohit Pandit, Secretary, Max Society of Academics Innovation and Research, Max Healthcare and Dr Jonathan Picker, CEO, Anuva.

The objective of the research will be to identify insights for precision medicine application across diseases including breast cancer, lung cancer, diabetes, cardiac disease, kidney disease, drug-resistant tuberculosis, and others.

As part of the five-year engagement, Max Healthcare will provide its expertise in clinical research and will serve as the clinical centre for data and sample collection from individuals who consent to share their data for the purpose of research.

On signing the MoU, Dr Sandeep Budhiraja, Group Medical Director, Max Healthcare said, “There is a lot to discover in the field of genetic and lifestyle diseases. With the coming of precision medicine and genomics, it has the potential to provide efficient solutions and transform the way we look at modern medicine today.”

Apart from research, the institutions will also explore the possibility of conducting joint training, fellowships, exchange visits, knowledge and technology transfer for cross-learning and capacity building in the fields of biomedical science and arenas of public health.

The partnership will also facilitate knowledge sharing and communication among scientists, epidemiologists and other stakeholders having a mutual interest in the discipline.